Hee-Sun Kim

Prof. Hee-Sun Kim


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2008 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MWMoon‐Sook Woo
Moon‐Sook Woo
JPJin‐Sun Park
Jin‐Sun Park
ICIn‐Young Choi
In‐Young Choi
WKWon‐Ki Kim
Won‐Ki Kim
HKHee-Sun Kim
Hee-Sun Kim
Recently, matrix metalloproteinases (MMPs) are emerging as important molecules in neuroinflammation as well as neuronal cell death. However, the role of MMPs in activated microglia remains unclear. In the present study, we found that expressions of MMP‐1, ‐3, ‐8 and ‐9 were significantly induced by single or combined treatment of immunostimulants lipopolysaccharide (LPS) or phorbol myristate acetate (PMA) in primary cultured microglia and BV2 microglial cells. Inhibition of MMP‐3 or ‐9 significantly suppressed the expression of iNOS and pro‐inflammatory cytokines and the activities of NF‐κB, AP‐1, and MAPK in LPS‐stimulated microglia. The results suggest that MMP‐3 and ‐9 both mediate LPS‐induced inflammatory reactions. Inhibition of reactive oxygen species (ROS) by N‐acetyl‐cysteine or diphenylene iodonium significantly suppressed the expression of MMP‐3, MMP‐9, NO and TNF‐α in LPS‐stimulated microglia, suggesting that ROS is an early signaling inducer in LPS‐stimulated microglial cells. MMP inhibitors also suppressed ROS production, suggesting a cross‐talk between ROS and MMPs. Collectively, the present study demonstrates that MMP‐3 and MMP‐9 play a role as inflammatory mediators in activated microglia. Pharmacological intervention of MMPs especially MMP‐3 and ‐9 would be a therapeutic strategy for the treatment of inflammatory diseases in the CNS caused by over‐activation of microglial cells.

1 April 2012 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
JPJin-Sun Park
Jin-Sun Park
JSJin A. Shin
Jin A. Shin
JJJi-Sun Jung
Ji-Sun Jung
JHJin-Won Hyun
Jin-Won Hyun
TLThi Kim Van Le
Thi Kim Van Le
HKHee-Sun Kim
Hee-Sun Kim
Microglial activation plays a pivotal role in the pathogenesis of various neurologic disorders, such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease. Thus, controlling microglial activation is a promising therapeutic strategy for such brain diseases. In the present study, we found that a ginseng saponin metabolite, compound K [20-O-d-glucopyranosyl-20(S)-protopanaxadiol], inhibited the expressions of inducible nitric-oxide synthase, proinflammatory cytokines, monocyte chemotactic protein-1, matrix metalloproteinase-3, and matrix metalloproteinase-9 in lipopolysaccharide (LPS)-stimulated BV2 microglial cells and primary cultured microglia. Subsequent mechanistic studies revealed that compound K suppressed microglial activation via inhibiting reactive oxygen species, mitogen-activated protein kinases, and nuclear factor-κB/activator protein-1 activities with enhancement of heme oxygenase-1/antioxidant response element signaling. To address the anti-inflammatory effects of compound K in vivo, we used two brain disease models of mice: sepsis (systemic inflammation) and cerebral ischemia. Compound K reduced the number of Iba1-positive activated microglia and inhibited the expressions of tumor necrosis factor-α and interleukin-1β in the LPS-induced sepsis brain. Furthermore, compound K reduced the infarct volume of ischemic brain induced by middle cerebral artery occlusion and suppressed microglial activation in the ischemic cortex. The results collectively suggest that compound K is a promising agent for prevention and/or treatment of cerebral ischemia and other neuroinflammatory disorders.

1 November 2017 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MCMin-Ji Choi
Min-Ji Choi
ELEun-Jung Lee
Eun-Jung Lee
JPJin-Sun Park
Jin-Sun Park
SKSu-Nam Kim
Su-Nam Kim
EPEun-Mi Park
Eun-Mi Park
HKHee-Sun Kim
Hee-Sun Kim

1 March 2019 in Phytomedicine
Verified
Journal Article
Closed access
GLGyeongjin Lee
Gyeongjin Lee
JPJin-Sun Park
Jin-Sun Park
ELEun-Jung Lee
Eun-Jung Lee
JAJung-Hyuck Ahn
Jung-Hyuck Ahn
HKHee-Sun Kim
Hee-Sun Kim

22 February 2016 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
YLYu Young Lee
Yu Young Lee
ELEun-Jung Lee
Eun-Jung Lee
JPJin-Sun Park
Jin-Sun Park
SJSe-Eun Jang
Se-Eun Jang
DKDong-Hyun Kim
Dong-Hyun Kim
HKHee-Sun Kim
Hee-Sun Kim

27 July 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SJSoo-Hyun Jung
Soo-Hyun Jung
MWMoon-Sook Woo
Moon-Sook Woo
SKSo-Young Kim
So-Young Kim
WKWon-Ki Kim
Won-Ki Kim
JHJin-Won Hyun
Jin-Won Hyun
HKHee-Sun Kim
Hee-Sun Kim
Aberrant expression of matrix metalloproteinase‐9 (MMP‐9) is implicated in the process of invasion and angiogenesis of malignant tumors as well as in inflammatory diseases of the CNS. Therefore, the development of compounds that can inhibit or suppress MMP‐9 is required to treat brain tumors. We investigated the effects of a ginseng saponin metabolite, compound K (20‐O‐(β‐D‐glucopyranosyl)‐20(S)‐protopanaxadiol), on MMP‐9 expression in human astroglioma cells. Compound K significantly inhibited the secretion and protein expression of MMP‐9 induced by PMA. The inhibitory effect of compound K on MMP‐9 expression correlated with decreased MMP‐9 mRNA levels and suppression of MMP‐9 promoter activity. The compound K–mediated inhibition of MMP‐9 gene expression appears to occur via AP‐1 because its DNA‐binding and transcriptional activities were suppressed by the agent. Furthermore, compound K significantly repressed the PMA‐mediated activation of p38 MAPK, ERK and JNK, which are upstream modulators of AP‐1. Finally, compound K inhibited the in vitro invasiveness of glioma cells. Therefore, inhibition of MMP‐9 expression by compound K might have therapeutic potential for controlling the growth and invasiveness of brain tumors.